Gemfibrozil, a lipid‐lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d‐galactose‐induced aging mice

Abstract Gemfibrozil (GFZ) is a lipid‐lowering drug with several other effects, such as antioxidant and anti‐inflammatory activities. In the current study, chronic d ‐galactose treatment ( d ‐gal, 150 mg/kg/day; i.p., 6 weeks) induced a model of accelerated aging in male mice and was used to study the behavioral, anti‐oxidative, and neuroprotective effects of GFZ (100 mg/kg/day; p.o.). Anxiety‐like behaviors were assessed using the elevated plus‐maze while working memory was measured by spontaneous alternation in a Y‐maze. Brain oxidative stress was determined by measuring malondialdehyde (MDA) levels, superoxide dismutase (SOD), and glutathione peroxidase (GPx) activities. Neuropathological evaluation of the brain with hematoxylin–eosin and Masson's trichrome staining was also performed. The results demonstrated that the anxious‐like phenotype and the cognitive impairments observed in d ‐gal‐treated mice could be prevented in those animals coadministered with GFZ. Besides, the decrease in SOD and GPx antioxidant enzymatic activities and increase of MDA levels were also prevented in the brains of d ‐gal plus GFZ treated mice. Preliminary hematoxylin–eosin staining also suggested neuroprotective effects of GFZ. The results of Masson's trichrome staining showed no evidence of fibrosis in brain sections of different experimental groups. The current data provide novel insights into GFZ in the d ‐galactose‐induced aging mouse model that open promising future research lines to determine inflammatory mediators and cell signaling underlying these effects.